CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


RTB101Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug1070 Honey Wiki 1.00
drug1595 Nigella Sativa / Black Cumin Wiki 0.71
drug1860 Placebos Wiki 0.24
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Randomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults ≥65 Years in a Nursing Home in Which ≥1 Person(s) Have Lab Confirmed COVID19

The purpose of this study is to determine if prophylaxis with RTB101 decreases the severity of laboratory-confirmed COVID-19 among adults ≥ 65 years who reside in a nursing homes in which one or more residents or staff have laboratory-confirmed COVID-19

NCT04409327 COVID19 Drug: RTB101 Drug: Placebo

Primary Outcomes

Measure: The percentage of subjects who develop laboratory-confirmed COVID-19: - with protocol-defined progressive symptoms OR - are hospitalized OR - die

Time: Through Week 4

Secondary Outcomes

Measure: The percentage of subjects who develop symptomatic laboratory-confirmed COVID-19 infection

Time: Through Week 4

Measure: Mortality rate in subjects who develop laboratory-confirmed COVID19

Time: Through Week 8

Measure: Percent of subjects who are hospitalized due to having one or more predefined COVID-19 symptoms and laboratory-confirmed SARS-CoV-2

Time: Through Week 4

Measure: Percent of subjects who require mechanical ventilation, noninvasive ventilation, high flow nasal canula oxygen delivery or ICU admission during the hospitalization for COVID19

Time: Through Week 8

Measure: Safety and tolerability will be assessed by report of AE/SAEs

Time: Through Week 5 and 8


No related HPO nodes (Using clinical trials)